Health
MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic...
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV) in Canada","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"MAVIRET received approval through Health Canada's Priority Review process, based on data from the Phase 3 M20-350 Study establishing it to be a highly efficacious treatment for people with acute hepatitis C.","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity and supports the World Health Organization's goal to eliminate HCV by 2030.","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Universal treatment of people with acute or chronic HCV can significantly reduce the spread of the disease.1","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":677,"olType":false},{"type":"text","content":"MONTREAL, Jan. 6, 2026 /CNW/ - AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.2 It is the first and only oral eight-week pan-genotypic treatment option approved in Canada.","length":397,"tagName":"p"},{"type":"image","alt":"AbbVie Canada (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"AbbVie Canada (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":123,"url":"https://media.zenfs.com/en/cnwgroup.com/9410b8813b5d72821c036bf3b4cb3798"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/A.o7LU8hKAF0TOh3WOf0nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/9410b8813b5d72821c036bf3b4cb3798","width":400,"height":123}},"href":"https://mma.prnewswire.com/media/2855089/AbbVie_Canada_MAVIRET_%C2%A0receives_Health_Canada_Approval_for_the_T.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hepatitis C is a liver infection caused by the hepatitis C virus, impacting over 214,000 Canadians.3 Acute hepatitis C is a shorter-term illness that occurs within the first six ...